vs

Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $120.4M, roughly 1.3× Hippo Holdings Inc.). Hippo Holdings Inc. runs the higher net margin — 5.0% vs -5.5%, a 10.5% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 18.2%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $9.1M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 18.9%).

Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

HIPO vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.3× larger
TARS
$151.7M
$120.4M
HIPO
Growing faster (revenue YoY)
TARS
TARS
+110.2% gap
TARS
128.4%
18.2%
HIPO
Higher net margin
HIPO
HIPO
10.5% more per $
HIPO
5.0%
-5.5%
TARS
More free cash flow
TARS
TARS
$3.9M more FCF
TARS
$13.0M
$9.1M
HIPO
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
18.9%
HIPO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HIPO
HIPO
TARS
TARS
Revenue
$120.4M
$151.7M
Net Profit
$6.0M
$-8.4M
Gross Margin
Operating Margin
5.6%
-5.3%
Net Margin
5.0%
-5.5%
Revenue YoY
18.2%
128.4%
Net Profit YoY
-86.4%
63.8%
EPS (diluted)
$0.31
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIPO
HIPO
TARS
TARS
Q4 25
$120.4M
$151.7M
Q3 25
$120.6M
$118.7M
Q2 25
$117.3M
$102.7M
Q1 25
$110.3M
$78.3M
Q4 24
$101.9M
$66.4M
Q3 24
$95.5M
$48.1M
Q2 24
$89.6M
$40.8M
Q1 24
$85.1M
$27.6M
Net Profit
HIPO
HIPO
TARS
TARS
Q4 25
$6.0M
$-8.4M
Q3 25
$98.1M
$-12.6M
Q2 25
$1.3M
$-20.3M
Q1 25
$-47.7M
$-25.1M
Q4 24
$44.2M
$-23.1M
Q3 24
$-8.5M
$-23.4M
Q2 24
$-40.5M
$-33.3M
Q1 24
$-35.7M
$-35.7M
Operating Margin
HIPO
HIPO
TARS
TARS
Q4 25
5.6%
-5.3%
Q3 25
81.3%
-12.2%
Q2 25
3.4%
-21.6%
Q1 25
-41.3%
-33.5%
Q4 24
46.3%
-36.8%
Q3 24
-5.4%
-52.3%
Q2 24
-40.7%
-81.6%
Q1 24
-38.7%
-136.5%
Net Margin
HIPO
HIPO
TARS
TARS
Q4 25
5.0%
-5.5%
Q3 25
81.3%
-10.6%
Q2 25
1.1%
-19.8%
Q1 25
-43.2%
-32.1%
Q4 24
43.4%
-34.8%
Q3 24
-8.9%
-48.7%
Q2 24
-45.2%
-81.6%
Q1 24
-42.0%
-129.4%
EPS (diluted)
HIPO
HIPO
TARS
TARS
Q4 25
$0.31
$-0.17
Q3 25
$3.77
$-0.30
Q2 25
$0.05
$-0.48
Q1 25
$-1.91
$-0.64
Q4 24
$1.81
$-0.57
Q3 24
$-0.34
$-0.61
Q2 24
$-1.64
$-0.88
Q1 24
$-1.47
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIPO
HIPO
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$218.3M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$436.1M
$343.4M
Total Assets
$1.9B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIPO
HIPO
TARS
TARS
Q4 25
$218.3M
$417.3M
Q3 25
$247.7M
$401.8M
Q2 25
$198.9M
$381.1M
Q1 25
$140.9M
$407.9M
Q4 24
$197.6M
$291.4M
Q3 24
$191.2M
$317.0M
Q2 24
$175.9M
$323.6M
Q1 24
$223.4M
$298.5M
Total Debt
HIPO
HIPO
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
HIPO
HIPO
TARS
TARS
Q4 25
$436.1M
$343.4M
Q3 25
$421.5M
$335.1M
Q2 25
$332.5M
$332.6M
Q1 25
$322.8M
$342.5M
Q4 24
$362.1M
$224.5M
Q3 24
$326.4M
$237.5M
Q2 24
$322.6M
$252.2M
Q1 24
$351.2M
$275.2M
Total Assets
HIPO
HIPO
TARS
TARS
Q4 25
$1.9B
$562.2M
Q3 25
$1.9B
$534.6M
Q2 25
$1.7B
$495.0M
Q1 25
$1.5B
$500.8M
Q4 24
$1.5B
$377.0M
Q3 24
$1.5B
$376.3M
Q2 24
$1.5B
$376.8M
Q1 24
$1.5B
$349.3M
Debt / Equity
HIPO
HIPO
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIPO
HIPO
TARS
TARS
Operating Cash FlowLast quarter
$9.2M
$19.3M
Free Cash FlowOCF − Capex
$9.1M
$13.0M
FCF MarginFCF / Revenue
7.6%
8.6%
Capex IntensityCapex / Revenue
0.1%
4.2%
Cash ConversionOCF / Net Profit
1.53×
TTM Free Cash FlowTrailing 4 quarters
$14.8M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIPO
HIPO
TARS
TARS
Q4 25
$9.2M
$19.3M
Q3 25
$16.9M
$18.3M
Q2 25
$24.7M
$-29.4M
Q1 25
$-35.6M
$-20.7M
Q4 24
$47.5M
$-22.2M
Q3 24
$46.8M
$-8.7M
Q2 24
$-10.6M
$-14.4M
Q1 24
$17.7M
$-37.8M
Free Cash Flow
HIPO
HIPO
TARS
TARS
Q4 25
$9.1M
$13.0M
Q3 25
$16.8M
$16.3M
Q2 25
$24.6M
$-30.4M
Q1 25
$-35.7M
$-21.2M
Q4 24
$47.2M
$-22.3M
Q3 24
$-8.9M
Q2 24
$-10.7M
$-15.4M
Q1 24
$17.6M
$-38.0M
FCF Margin
HIPO
HIPO
TARS
TARS
Q4 25
7.6%
8.6%
Q3 25
13.9%
13.8%
Q2 25
21.0%
-29.6%
Q1 25
-32.4%
-27.1%
Q4 24
46.3%
-33.5%
Q3 24
-18.6%
Q2 24
-11.9%
-37.8%
Q1 24
20.7%
-137.5%
Capex Intensity
HIPO
HIPO
TARS
TARS
Q4 25
0.1%
4.2%
Q3 25
0.1%
1.6%
Q2 25
0.1%
1.0%
Q1 25
0.1%
0.8%
Q4 24
0.3%
0.1%
Q3 24
0.0%
0.6%
Q2 24
0.1%
2.5%
Q1 24
0.1%
0.6%
Cash Conversion
HIPO
HIPO
TARS
TARS
Q4 25
1.53×
Q3 25
0.17×
Q2 25
19.00×
Q1 25
Q4 24
1.07×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons